Pharmaceutical

CTX-310 by CRISPR Therapeutics for Heterozygous familial hypercholesterolemia (heFH): Likelihood of Approval

CTX-310 is under clinical development by CRISPR Therapeutics and currently in Phase II for Heterozygous familial hypercholesterolemia (heFH).

Jul 6, 2024 - 04:00
CTX-310 is under clinical development by CRISPR Therapeutics and currently in Phase II for Heterozygous familial hypercholesterolemia (heFH).
Read the original article

Tags:

Previous Article

NN-6561 by Novo Nordisk for Metabolic Dysfunction-Associated Steatohepatitis (MA...

Next Article

CTX-310 by CRISPR Therapeutics for Homozygous Familial Hypercholesterolemia (HoF...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pipelines from high school to health care jobs to be created by new Bloomberg Philanthropies initiative

STAT+: Pipelines from high school to health care jobs t...

Jan 18, 2024

STAT+: Feng Zhang’s year-old CRISPR delivery startup Aera lays off quarter of staff

STAT+: Feng Zhang’s year-old CRISPR delivery startup Ae...

Jan 4, 2024

Sosei Heptares hits discovery milestone in GPCR deal with Genentech

Sosei Heptares hits discovery milestone in GPCR deal wi...

Oct 31, 2023